28 May 2021 | 09:18am
StockMarketWire.com - GSTechnologies said it had signed a collaboration agreement with Wise MPay, the Singaporean blockchain payment solution provider.
Under the agreement, Wise MPay would provide the company with software and services to facilitate the company s plans launch GS Money, a neobanking platform providing digital money solutions.
The agreement builds upon the memorandum of understanding between the Company and Wise MPay announced on 21 April 2021.
At 9:18am: [LON:GST] share price was 0p at 0.2p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details:
14 April 2021 | 08:38am
StockMarketWire.com - Biotechnology company Destiny Pharma reported wider annual losses on increased costs amid efforts to progress its nasal gel, used in the prevention of post-surgical infections, through a clinical trial.
For the year ended 31 December 2020, pre-tax losses widen to £6.5 million from £5.5 million year-on-year.
Research and development costs rose to £792,343 from £621,447. Our key focus during 2020 was on progressing our lead XF-73 nasal gel programme through a Phase 2b clinical trial, which accounts for the majority of our R&D spend during the year, the company said.
Looking ahead, the company said it had cash runway through to Q4 2022 after closing £10.4 million equity funding round in December to fund the NTCD-M3 acquisition.
15 March 2021 | 09:49am
StockMarketWire.com - Biotechnology company Destiny Pharma said it had entered into an agreement under which the US government s National Institute of Allergy and Infectious Diseases would evaluate the formulation of the company s drug to prevent postsurgical staphylococcal infections.
Destiny Pharma would utilize preclinical National Institute of Allergy and Infectious Diseases services programme to complete the preclinical safety studies that would support the planned clinical development in serious wound infections.
Destiny Pharma will provide the XF-73 formulation to be tested in these preclinical studies and the project was planned to complete in 2022.
At 9:49am: [LON:DEST] Destiny Pharma Plc share price was 0p at 68.5p
Director Deals
8 January 2021 | 06:03am
StockMarketWire.com - Philip Rodgers, Chairman, bought 9,000 shares in the company on the 6th January 2021 at a price of £0.88. The Director now holds 47,462 shares.
Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details: